Market Cap | 41.74K | P/E | - | EPS this Y | - | Ern Qtrly Grth | 18.60% |
Income | 270.28M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -91.00% |
Sales | 2.36B | PEG | - | EPS past 5Y | - | 200D Avg Chg | -98.00% |
Dividend | 115,500.00% | Price/Book | 0.00 | EPS next 5Y | - | 52W High Chg | -100.00% |
Recommedations | - | Quick Ratio | 1.43 | Shares Outstanding | 208.70M | 52W Low Chg | - |
Insider Own | - | ROA | 6.19% | Shares Float | 196.22M | Beta | 3,091.22 |
Inst Own | - | ROE | 18.98% | Shares Shorted/Prior | -/- | Price | 0.00020 |
Gross Margin | 42.70% | Profit Margin | 11.45% | Avg. Volume | 10,568 | Target Price | - |
Oper. Margin | 18.07% | Earnings Date | - | Volume | 179 | Change | 0.00% |
NMC Health plc provides healthcare services in the United Arab Emirates, the United Kingdom, Spain, and internationally. The company owns and manages healthcare facilities, including hospitals, medical centers, long term care facilities, day surgery centers, fertility clinics, and home health services providers. The company offers medical services comprising diagnostic, and in and outpatient services, as well as research and medical services in the field of gynecology, obstetrics, and human reproduction; and management services in respect of hospitals, as well as retails pharmaceutical goods. NMC Health plc was founded in 1974 and is based in London, United Kingdom.
JP Morgan | Overweight | Nov 21, 18 |